James Chappell
Denver, CONPI 1598726440
Payments from drug & device makers
Across 1,012 payments — averaging $414.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$402K
- Boehringer Ingelheim$8K
- AstraZeneca$7K
- Medtronic$525
- Novo Nordisk$402
- Kowa Pharmaceuticals America, Inc.$190
- plus $886 from 13 others
What the payments were for
- Consulting fees$6,1751%
- Speaking & faculty fees$378,32590%
- Travel & lodging$25,0346%
- Food & beverage$10,1272%
- Education$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 880 | $402,409 |
| Boehringer Ingelheim | 20 | $8,249 |
| AstraZeneca | 29 | $7,054 |
| Medtronic(2 entities) | 34 | $525 |
| Novo Nordisk | 7 | $402 |
| Kowa Pharmaceuticals America, Inc. | 11 | $190 |
| Amgen | 5 | $187 |
| AbbVie | 9 | $173 |
| Rhythm Pharmaceuticals, Inc. | 1 | $148 |
| Chiesi USA, Inc. | 1 | $112 |
| Sequel Med Tech, LLC | 2 | $65 |
| IBSA Pharma Inc. | 3 | $49 |
| Dexcom, Inc. | 2 | $35 |
| Merck | 2 | $32 |
| Insulet Corporation | 2 | $24 |
| Mannkind Corporation | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Abbott | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 419 | $632,439 |
| JardianceEmpagliflozin | 258 | $334,769 |
| TrulicityDulaglutide | 86 | $118,871 |
| FarxigaDapagliflozin Propanediol | 56 | $82,419 |
| SynjardyEmpagliflozin/Metformin Hcl | 33 | $41,633 |
| OzempicSemaglutide | 15 | $41,034 |
| SynthroidLevothyroxine Sodium | 271 | $26,688 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $18,104 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $13,037 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $9,208 |
| Praluent PenAlirocumab | 15 | $7,648 |
| VascepaIcosapent Ethyl | 19 | $5,776 |
| HumalogInsulin Lispro | 13 | $3,557 |
| Rosuvastatin Calcium | 134 | $1,885 |
| UnithroidLevothyroxine Sodium | 17 | $1,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $402,409 | $755,439532 claims |
| Boehringer IngelheimJardiance, Synjardy | $8,249 | $376,402291 claims |
| AstraZenecaFarxiga | $7,054 | $82,41956 claims |
| Novo NordiskOzempic | $402 | $41,03415 claims |
| AbbVieSynthroid | $173 | $26,688271 claims |
| Amneal Pharmaceuticals LLCUnithroid | $13 | $1,52117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.